Cannabis Dosing in Family Medicine: Evidence-Based Care for Endocannabinoid System Regulation
Clinical Takeaway
Cannabis use for anxiety showed different daily outcomes depending on whether people used flower or edible products, with THC and CBD combinations producing varying effects across the two formats. Both product types reduced anxiety over the 30-day period, but the pattern and magnitude of daily relief differed meaningfully between flower and edibles. Patients choosing cannabis for anxiety management should discuss product format alongside cannabinoid content with their clinician, as delivery method appears to influence therapeutic outcomes.
#12 Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products.
Citation: Rosa Luiza et al.. Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products.. International journal of environmental research and public health. 2026. PMID: 41752306.
Design: 5 Journal: 0 N: 2 Recency: 3 Pop: 2 Human: 1 Risk: -2
- Preclinical only
Abstract: Research shows that delta-9-tetrahydrocannabinol (THC) is linked to increased anxiety, while cannabidiol (CBD) may have anxiolytic effects. Cannabis use is often driven by coping with anxiety, though its daily impact on anxiety remains unclear. This study examined daily associations between cannabis use and anxiety across 30 days in adults who wanted to use cannabis for anxiety relief. Participants (N = 345) used flower or edible products ad libitum and were randomly assigned to groups by product type (CBD, THC, or THC + CBD). Each day, participants reported cannabis use in the past 24 h and rated their anxiety. Linear mixed-effects models tested whether anxiety changed over time, differed by cannabinoid group, and varied with use. Anxiety significantly decreased over the study period in both flower and edibles groups. In the flower group, THC + CBD and CBD products had greater decreases in anxiety (39.5% and 34.8%, respectively) compared to THC products (7.8%). In the edibles group, when participants used CBD products, this was associated with a 24.9% reduction in anxiety over the 30 days. Findings underscore the importance of distinguishing cannabis effects by product type and cannabinoid composition and suggest that CBD-dominant edibles were associated with less anxiety over time in this naturalistic study.
What This Study Teaches Us
When adults used cannabis specifically for anxiety relief over 30 days, anxiety decreased in both flower and edible forms, but CBD-dominant products showed substantially larger improvements (25-40% reduction) than THC-alone products (8% reduction). Product type and cannabinoid composition matter more than we might assume from general cannabis-anxiety literature.
Why This Matters Clinically
Clinicians counseling anxious patients on cannabis need to know that not all cannabis is equally effective for anxiety, and that CBD-dominant formulations (especially edibles) appear to have a clearer anxiolytic signal than THC-heavy products. Patients self-treating anxiety with THC-dominant flower may be working against their stated goal.
Study Snapshot
| Study Design | Randomized controlled trial with naturalistic, ad libitum cannabis use over 30 days |
| Population | N=345 adults motivated to use cannabis for anxiety relief; demographics not specified in abstract |
| Intervention | Randomly assigned to flower or edible products in one of three cannabinoid groups (CBD, THC, or THC+CBD); participants chose frequency and timing |
| Primary Outcome | Daily self-reported anxiety ratings over 30-day period, analyzed by product type and cannabinoid composition |
| Key Result | Flower THC+CBD: 39.5% anxiety reduction; flower CBD: 34.8% reduction; flower THC: 7.8% reduction. Edible CBD: 24.9% reduction |
Where This Paper Deserves Skepticism
The abstract is thin on critical methodological detail: no information on baseline anxiety severity, demographic representativeness, blinding status, or dropout rates. The ad libitum dosing design makes it impossible to isolate dose-response, and self-reported daily anxiety is vulnerable to recall bias and expectancy effects. No mention of funding source or conflict of interest. We do not know if participants were treatment-naive or experienced users, which could shift generalizability. The large reported improvements (especially 39.5%) should prompt caution about unmeasured confounders or regression to the mean.
Dr. Caplan’s Take
I find this study clinically interesting because it aligns with what we see in practice: CBD-dominant formulations do seem to help anxiety more than THC-dominant ones, and the product form (flower vs. edible) appears to matter. That said, I’m cautious about the magnitude of effects reported here. The study design is naturalistic and open-label in nature, which means expectancy and motivation are baked into the results. Before I change my counseling based on this, I’d want to see replication with stronger methodology, longer follow-up, and better measurement of baseline anxiety and confounders like stress, sleep, and concurrent medications.
Clinical Bottom Line
For patients seeking cannabis for anxiety, a CBD-dominant edible or a balanced THC+CBD flower product shows more promise than THC-alone flower, but clinicians should interpret these findings as directional rather than definitive and remain alert to expectancy effects in patient reports.
| |
Have thoughts on this? Share it:
